PartnershipMay 28, 2026, 04:53 PM
FOXO Licenses Epigenetics IP to LongevityFP; 3% Royalty, $1.3M Cap
AI Summary
FOXO Technologies Inc. and its subsidiary FOXO Labs, Inc. entered into a Strategic Technology License Agreement with LongevityFP Technologies, LLC, controlled by FOXO's founder Jon R. Sabes. The agreement grants LongevityFP an exclusive, worldwide license to commercialize FOXO's epigenetics intellectual property, including patents and datasets. FOXO will receive a 3% royalty on net revenues, capped at $1.3 million, and retains a 40% equity interest option in the epigenetics enterprise if LongevityFP exercises its option to acquire majority ownership of FOXO Labs. This partnership aims to commercialize the technology and resolves prior matters between the parties.
Key Highlights
- FOXO granted LongevityFP Technologies an exclusive, worldwide license for its epigenetics IP portfolio.
- Licensed IP includes two issued U.S. patents and a 13,000+ individual epigenetic dataset.
- LongevityFP will pay FOXO a 3% royalty on net revenues, capped at $1,300,000.
- LongevityFP received a 10-year option to acquire majority ownership of FOXO Labs, Inc.
- Upon option exercise, FOXO would retain a 40% equity interest in the resulting epigenetics enterprise.
- The agreement resolves all prior matters between FOXO and Jon R. Sabes.
- FOXO management can now focus on its core healthcare services operations.
Price Impact
More from FOXO